MX347669B - Metodo para disminuir el dolor articular inducido por el ejercicio en mamiferos no artriticos. - Google Patents

Metodo para disminuir el dolor articular inducido por el ejercicio en mamiferos no artriticos.

Info

Publication number
MX347669B
MX347669B MX2014002934A MX2014002934A MX347669B MX 347669 B MX347669 B MX 347669B MX 2014002934 A MX2014002934 A MX 2014002934A MX 2014002934 A MX2014002934 A MX 2014002934A MX 347669 B MX347669 B MX 347669B
Authority
MX
Mexico
Prior art keywords
joint pain
induced joint
reducing exercise
mammals
arthritic
Prior art date
Application number
MX2014002934A
Other languages
English (en)
Other versions
MX2014002934A (es
Inventor
Dijkstra Paul
C Lau Francis
Lugo James
M Saiyed Zainulabedin
Original Assignee
Interhealth Nutraceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Interhealth Nutraceuticals Inc filed Critical Interhealth Nutraceuticals Inc
Publication of MX2014002934A publication Critical patent/MX2014002934A/es
Publication of MX347669B publication Critical patent/MX347669B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/34—Muscles; Smooth muscle cells; Heart; Cardiac stem cells; Myoblasts; Myocytes; Cardiomyocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente invención se refiere a un uso de colágeno tipo II no desnaturalizado en la manufactura de un medicamento para el tratamiento del dolor articular inducido por el ejercicio en un mamífero no artrítico, en donde el medicamento está adaptado para ser administrable en una cantidad eficaz para disminuir el dolor articular inducido por el ejercicio.
MX2014002934A 2013-10-24 2014-01-13 Metodo para disminuir el dolor articular inducido por el ejercicio en mamiferos no artriticos. MX347669B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361895332P 2013-10-24 2013-10-24
PCT/US2014/011303 WO2015060888A1 (en) 2013-10-24 2014-01-13 Method of reducing exercise-induced joint pain in non-arthritic mammals
US14/153,841 US9066926B2 (en) 2013-10-24 2014-01-13 Method of reducing exercise-induced joint pain in non-arthritic mammals

Publications (2)

Publication Number Publication Date
MX2014002934A MX2014002934A (es) 2015-09-21
MX347669B true MX347669B (es) 2017-05-08

Family

ID=51610711

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014002934A MX347669B (es) 2013-10-24 2014-01-13 Metodo para disminuir el dolor articular inducido por el ejercicio en mamiferos no artriticos.

Country Status (14)

Country Link
US (1) US9066926B2 (es)
KR (1) KR101664290B1 (es)
AR (1) AR095104A1 (es)
AU (1) AU2014202041B8 (es)
BR (1) BR112014011741A2 (es)
CA (1) CA2846644C (es)
CL (1) CL2014001281A1 (es)
CO (1) CO7020846A2 (es)
IN (1) IN2014DE00193A (es)
MX (1) MX347669B (es)
MY (1) MY180106A (es)
PH (1) PH12014501453A1 (es)
SG (1) SG11201403524RA (es)
WO (1) WO2015060888A1 (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10226513B2 (en) 2015-01-09 2019-03-12 Mark Terrell Smith Method and composition to prevent or improve symptoms of musculoskeletal distress degeneration
EP3512409A1 (en) * 2016-09-16 2019-07-24 Boston Scientific Neuromodulation Corporation System for pain management using heart sounds
EP3518736B1 (en) 2016-09-27 2021-08-18 Boston Scientific Neuromodulation Corporation System for pain management using objective pain measure
US10610688B2 (en) 2016-09-27 2020-04-07 Boston Scientific Neuromodulation Corporation Systems and methods for closed-loop pain management
US11793217B1 (en) 2016-10-04 2023-10-24 Lonza Greenwood Llc Method of manufacture and pasteurization of products containing undenatured collagen
EP3526007A4 (en) 2016-10-12 2020-05-27 Advanced Biomatrix, Inc. THREE-DIMENSIONAL (3-D) PRINTING INKS MANUFACTURED FROM NATURAL EXTRACELLULAR MATRIX MOLECULES
US10667747B2 (en) 2016-10-25 2020-06-02 Boston Scientific Neuromodulation Corporation Method and apparatus for pain control using baroreflex sensitivity during posture change
US11089997B2 (en) 2017-01-11 2021-08-17 Boston Scientific Neuromodulation Corporation Patient-specific calibration of pain quantification
US10729905B2 (en) 2017-01-11 2020-08-04 Boston Scientific Neuromodulation Corporation Pain management based on muscle tension measurements
WO2018132529A1 (en) 2017-01-11 2018-07-19 Boston Scientific Neuromodulation Corporation Pain management based on brain activity monitoring
EP3568861B1 (en) 2017-01-11 2024-12-11 Boston Scientific Neuromodulation Corporation Pain management based on emotional expression measurements
US10631777B2 (en) 2017-01-11 2020-04-28 Boston Scientific Neuromodulation Corporation Pain management based on functional measurements
US10631776B2 (en) 2017-01-11 2020-04-28 Boston Scientific Neuromodulation Corporation Pain management based on respiration-mediated heart rates
US10960210B2 (en) 2017-02-10 2021-03-30 Boston Scientific Neuromodulation Corporation Method and apparatus for pain management with sleep detection
CN106713191B (zh) * 2017-02-28 2020-09-08 西安电子科技大学 一种多级搜索sage方法
CN107048412A (zh) * 2017-04-26 2017-08-18 北京盛美诺生物技术有限公司 一种含有ⅱ型胶原蛋白的咀嚼型产品
WO2019018206A1 (en) 2017-07-18 2019-01-24 Boston Scientific Neuromodulation Corporation SELF-BASED PAIN MANAGEMENT SYSTEMS AND METHODS
EP3655018B1 (en) 2017-08-21 2025-02-26 Lonza Greenwood LLC Composition and nutritional supplement made therefrom
CN111093770A (zh) * 2017-08-31 2020-05-01 伦萨有限责任公司 健康促进组合物和使用补剂方法的相关应用
IT201700111939A1 (it) * 2017-10-05 2019-04-05 Jointherapeutics S R L Composizione farmaceutica per l’uso nel trattamento di stati infiammatori
BR112021000860A2 (pt) * 2018-07-16 2021-04-13 Lonza Consumer Health Inc. Suplemento de colágeno e matéria celular e método para administrar o mesmo
WO2021016665A1 (en) * 2019-07-30 2021-02-04 Atp Institute Pty Ltd A gummy composition
EP4037503A1 (en) 2019-09-30 2022-08-10 Lonza Consumer Health Inc. Cannabinoid product for improving musculoskeletal health
AU2021213722A1 (en) * 2020-01-29 2022-07-28 Lonza Greenwood Llc Joint health composition and use thereof in healthy mammals
MX2022010745A (es) 2020-03-03 2022-11-08 Lonza Greenwood Llc Colageno tipo ii sin desnaturalizar en aplicaciones de alimentos y bebidas y usos de este.
JP2023518688A (ja) 2020-03-24 2023-05-08 ロンザ・グリーンウッド・エルエルシー 動物用食品およびおやつにおける非変性ｉｉ型コラーゲン
US20230256060A1 (en) 2020-06-12 2023-08-17 Lonza Greenwood Llc Undenatured Type II Collagen as a Supplement for Improved Endurance, Lipid Metabolism, and Oxidative Stress
WO2022040026A1 (en) * 2020-08-19 2022-02-24 Lonza Consumer Health Inc. Method for improving inflammation, joint health, joint mobility, and joint comfort in healthy mammals
CN115120618B (zh) * 2021-03-23 2024-01-26 安徽盛美诺生物技术有限公司 具有改善免疫应答作用的软骨提取物、其制备方法及其用途
JP2024543411A (ja) * 2021-11-12 2024-11-21 ロンザ・グリーンウッド・エルエルシー 骨格関節を治療するための方法並びに組成物及びその使用
KR102771944B1 (ko) * 2023-09-25 2025-02-26 (주)온오퍼 고함량 액티브 성분을 갖는 반려동물용 츄 형태 영양제

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5399347A (en) 1987-06-24 1995-03-21 Autoimmune, Inc. Method of treating rheumatoid arthritis with type II collagen
WO1993008784A1 (en) 1991-11-08 1993-05-13 Gunilla Lofgren Nisser Partially occluded contact lens for treating visual and/or brain disorder
US5645851A (en) 1994-02-28 1997-07-08 Moore; Eugene R. Product for alleviating the symptons of arthritis in mammals
US5529786A (en) 1994-02-28 1996-06-25 Moore; Eugene R. Process and product for treatment of rheumatoid arthritis
US5637321A (en) 1994-02-28 1997-06-10 Moore; Eugene R. Method for preparing animal tissue for use in alleviating the symptoms of arthritis in mammals
US6162787A (en) 1999-04-02 2000-12-19 Immudyne, Inc. Methods for treating arthritis using collagen type II, glucosamine chondroitin sulfate, and compositions
US6372794B1 (en) * 1999-08-26 2002-04-16 Marcel E. Nimni Method for alleviating arthritis in mammals
US20020086070A1 (en) 2000-03-11 2002-07-04 Kuhrts Eric Hauser Anti-inflammatory and connective tissue repair formulations
US7083820B2 (en) 2000-09-29 2006-08-01 Schilling Marvin L Method for producing biologically active products
JP2003048850A (ja) 2001-06-01 2003-02-21 Nippon Meat Packers Inc 関節傷害治療剤及び機能性食品
US20060062859A1 (en) * 2004-08-05 2006-03-23 Kenneth Blum Composition and method to optimize and customize nutritional supplement formulations by measuring genetic and metabolomic contributing factors to disease diagnosis, stratification, prognosis, metabolism, and therapeutic outcomes
FR2900155B1 (fr) 2006-04-21 2008-06-27 Diana Naturals Sa Hydrolisat de cartilage aviaire, procede d'obtention et utilisations
US20100215731A1 (en) 2009-02-20 2010-08-26 Maastricht University Method for improving cartilage repair and/or preventing cartilage degeneration in a joint
US20110218151A1 (en) * 2010-03-04 2011-09-08 Joar Opheim Substances for promoting healthy joint function comprising omega-3 polyunsaturated fatty acids or drivatives thereof, undenatured type ii collagen and, optionally, glucosamine sulfate
CN101822684B (zh) 2010-05-27 2012-08-15 江苏江山制药有限公司 用于防治骨关节痛的复方组合制剂及其制备方法
US20120294898A1 (en) 2011-05-19 2012-11-22 Warsaw Orthopedic, Inc. Injectable dbm for soft tissue repair
CN102423487B (zh) 2011-12-23 2014-04-16 内蒙古伊利实业集团股份有限公司 一种骨关节保健组合物及其应用
CN103203012A (zh) 2012-01-12 2013-07-17 深圳市麦金利实业有限公司 关节保健品

Also Published As

Publication number Publication date
PH12014501453B1 (en) 2015-01-21
AU2014202041B8 (en) 2020-04-02
CA2846644C (en) 2018-05-01
KR20150059132A (ko) 2015-05-29
CA2846644A1 (en) 2015-07-13
AU2014202041A1 (en) 2015-05-14
MX2014002934A (es) 2015-09-21
CL2014001281A1 (es) 2015-10-30
KR101664290B1 (ko) 2016-10-11
AU2014202041B2 (en) 2019-11-28
IN2014DE00193A (es) 2015-05-01
WO2015060888A1 (en) 2015-04-30
BR112014011741A2 (pt) 2017-05-30
CO7020846A2 (es) 2014-08-11
SG11201403524RA (en) 2015-05-28
MY180106A (en) 2020-11-23
US20150119335A1 (en) 2015-04-30
US9066926B2 (en) 2015-06-30
AR095104A1 (es) 2015-09-30
PH12014501453A1 (en) 2015-01-21

Similar Documents

Publication Publication Date Title
MY180106A (en) Method of reducing exercise-induced joint pain in non-arthritic mammals
UA110813C2 (uk) Лікування ліподистрофії
MY172578A (en) Oral dosing of glp-1 compounds
MX2016009437A (es) Metodo para reducir la produccion de gas total y/o la produccion de metano en un animal rumiante.
IN2014CN03887A (es)
MX365614B (es) Composiciones utiles para tratar trastornos relacionados con kit.
IN2015DN03322A (es)
AR095977A1 (es) Un procedimiento para aumentar la formación de ácido piroglutámico de una proteína
PH12015501071A1 (en) Combination therapy of anti-her3 antibodies
EA201600026A1 (ru) Бактериальная гиалуронидаза и способ ее производства
MX359181B (es) Hidrolizado de colágeno y uso del mismo.
PL2860256T3 (pl) Sposób wytwarzania L-aminokwasów
PH12016500598A1 (en) Protoxin-ii variants and methods of use
PH12016500497A1 (en) Compositions for the treatment of hypertension and/or fibrosis
PH12016500495A1 (en) Compositions for the treatment of hypertension and/or fibrosis
EP3696190A3 (en) Methods
EA201690075A1 (ru) Способ лечения внутриклеточной инфекции
MX2016005545A (es) Analogo de la relaxina humana, composicion farmaceutica del mismo y aplicacion farmaceutica del mismo.
IN2013MU01113A (es)
MX2017013667A (es) Uso de un aditivo de combustible en combustible diesel para reducir el consumo de combustible en un motor diesel.
IL242911B (en) Tin-117m for treatment of immune, inflammatory and degenerative arthritides
MX2016005645A (es) Composicion farmaceutica topica de acitretina.
PH12018500339A1 (en) Lysobactin for use in the treatment of bovine mastitis
CY1119212T1 (el) Χρηση του odiparcil στη θεραπεια μιας μυκοπολυσακχαριδωσης
MY173051A (en) Microorganism having producing ability of quinolinic acid and method for producing quinolinic acid using the microorganism

Legal Events

Date Code Title Description
FG Grant or registration